Cargando…

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy

BACKGROUND: Epidermal growth factor receptor (EGFR) activation is associated with increased production of interleukin 6 (IL6), which is intensified by radiotherapy (RT) induced inflammatory response. Elevated IL6 levels intensifies RT-induced anemia by upregulating hepcidin causing functional iron d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maahs, Lucas, Ghanem, Ahmed I., Gutta, Radhika, Tang, Amy, Arya, Swarn, Al Saheli, Zaid, Ali, Haythem, Chang, Steven, Tam, Samantha, Wu, Vivian, Siddiqui, Farzan, Sheqwara, Jawad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175328/ https://www.ncbi.nlm.nih.gov/pubmed/35672745 http://dx.doi.org/10.1186/s12885-022-09708-9

Ejemplares similares

The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy
por: Ghanem, Ahmed I., et al.
Publicado: (2019)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
por: Krishnamurthy, Sapna, et al.
Publicado: (2022)

A Case of Symptomatic Cerebral Radiation Necrosis for an Extra-Cranial Neoplasm from Conventional Radiotherapy With Concurrent Immunotherapy
por: Gutta, Radhika, et al.
Publicado: (2021)

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
por: Elghouche, Alhasan, et al.
Publicado: (2016)

Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer
por: Huang, Tai-Lin, et al.
Publicado: (2022)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Evaluation of a nurse-led aftercare intervention for patients with head and neck cancer treated with radiotherapy and cisplatin or cetuximab
por: Braat, Cora, et al.
Publicado: (2022)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
por: Hecht, Markus, et al.
Publicado: (2021)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
por: Tang, Wen-Hua, et al.
Publicado: (2020)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Hematologic Characteristics of Surviving Versus Non-Surviving COVID-19 Patients in Critical Care Units: Inner-City Hospital Experience, Detroit, MI
por: Balanchivadze, Nino, et al.
Publicado: (2020)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Does Anemia Have a Potential Effect on Type 2 Hepatorenal Syndrome?
por: Bizid, Sondes, et al.
Publicado: (2020)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
por: Berger, Bernhard, et al.
Publicado: (2008)

A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
por: Venkateshulu, Shruthi, et al.
Publicado: (2021)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
por: Okano, Susumu, et al.
Publicado: (2013)

Homologous platelet gel on radiation-induced dermatitis in a patient receiving head and neck radiotherapy plus cetuximab: A case report
por: Guberti, Monica, et al.
Publicado: (2023)

A Rare Cardiac Cavernous Hemangioma Treated with Radiotherapy
por: Wang, Pule, et al.
Publicado: (2022)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck()
por: de Llobet, Lara I., et al.
Publicado: (2014)

Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study
por: Imai, Chiaki, et al.
Publicado: (2022)

Correlation between ABO Blood Groups and Disease Severity and Mortality in Hospitalized COVID-19 Patients
por: Ramo, Aula, et al.
Publicado: (2020)

Biopsychosocial impact on caregivers of head and neck cancer patients undergoing radiotherapy at a tertiary care hospital
por: Jodalli, Praveen, et al.
Publicado: (2022)

Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report
por: Azad, Arun
Publicado: (2009)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qs1b1shj9i60qagurke82i9b4v